Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase

A. Reiff, M. Zastrow, B. C. Sun, S. Takei, H. Mitsuhada, B. Bernstein, Donald L Durden

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective. To evaluate the safety and efficacy of L-asparaginase as an immunosuppressive agent in a mouse model of rheumatoid arthritis. Methods. Male DBA/1 mice with collagen-induced arthritis (CIA) were treated at different intervals with various doses of native and pegylated L-asparaginase from E. coli. The mice were observed for 4 weeks during which time arthritis was scored. Outcome parameters included effect on severity and progression of established arthritis as well as prevention of disease. In addition, X-rays from the affected joints were obtained for comparison. Results. Both native L-asparaginase at a dose of 50 IU/injection intraperitoneally three days a week and pegylated asparaginase (PEG-L-asparaginase) at a dose of 25 IU/injection twice a week, significantly reduced the mean arthritic score (MAS) in mice with established arthritis (p < 0.001 for PEG-L-asparaginase). When native L-asparaginase was administered before the onset of arthritis (days 14-post immunization) the number of mice developing arthritis as well as the number of arthritic paws and the severity of arthritis in the treatment group were significantly decreased (p < 0.0001). Significant differences were found in the X-ray evaluation between treated and control mice. None of the animals died due to drug related events or showed signs of asparaginase induced toxicity. Conclusion. Our data provide the first direct evidence that L-asparaginase is a potent antiarthritic agent and may represent an effective second line agent for future treatment studies in juvenile and adult rheumatoid arthritis.

Original languageEnglish (US)
Pages (from-to)639-646
Number of pages8
JournalClinical and experimental rheumatology
Volume19
Issue number6
StatePublished - Dec 1 2001

Fingerprint

Asparaginase
Inbred DBA Mouse
Experimental Arthritis
Arthritis
Therapeutics
X-Rays
Injections
Juvenile Arthritis
Immunosuppressive Agents
Immunization
Rheumatoid Arthritis
Joints
Escherichia coli
Safety

Keywords

  • CIA
  • L-asparaginase
  • Treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Reiff, A., Zastrow, M., Sun, B. C., Takei, S., Mitsuhada, H., Bernstein, B., & Durden, D. L. (2001). Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. Clinical and experimental rheumatology, 19(6), 639-646.

Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. / Reiff, A.; Zastrow, M.; Sun, B. C.; Takei, S.; Mitsuhada, H.; Bernstein, B.; Durden, Donald L.

In: Clinical and experimental rheumatology, Vol. 19, No. 6, 01.12.2001, p. 639-646.

Research output: Contribution to journalArticle

Reiff, A, Zastrow, M, Sun, BC, Takei, S, Mitsuhada, H, Bernstein, B & Durden, DL 2001, 'Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase', Clinical and experimental rheumatology, vol. 19, no. 6, pp. 639-646.
Reiff A, Zastrow M, Sun BC, Takei S, Mitsuhada H, Bernstein B et al. Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. Clinical and experimental rheumatology. 2001 Dec 1;19(6):639-646.
Reiff, A. ; Zastrow, M. ; Sun, B. C. ; Takei, S. ; Mitsuhada, H. ; Bernstein, B. ; Durden, Donald L. / Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. In: Clinical and experimental rheumatology. 2001 ; Vol. 19, No. 6. pp. 639-646.
@article{c183d847ed244025b358327ae9b6ba27,
title = "Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase",
abstract = "Objective. To evaluate the safety and efficacy of L-asparaginase as an immunosuppressive agent in a mouse model of rheumatoid arthritis. Methods. Male DBA/1 mice with collagen-induced arthritis (CIA) were treated at different intervals with various doses of native and pegylated L-asparaginase from E. coli. The mice were observed for 4 weeks during which time arthritis was scored. Outcome parameters included effect on severity and progression of established arthritis as well as prevention of disease. In addition, X-rays from the affected joints were obtained for comparison. Results. Both native L-asparaginase at a dose of 50 IU/injection intraperitoneally three days a week and pegylated asparaginase (PEG-L-asparaginase) at a dose of 25 IU/injection twice a week, significantly reduced the mean arthritic score (MAS) in mice with established arthritis (p < 0.001 for PEG-L-asparaginase). When native L-asparaginase was administered before the onset of arthritis (days 14-post immunization) the number of mice developing arthritis as well as the number of arthritic paws and the severity of arthritis in the treatment group were significantly decreased (p < 0.0001). Significant differences were found in the X-ray evaluation between treated and control mice. None of the animals died due to drug related events or showed signs of asparaginase induced toxicity. Conclusion. Our data provide the first direct evidence that L-asparaginase is a potent antiarthritic agent and may represent an effective second line agent for future treatment studies in juvenile and adult rheumatoid arthritis.",
keywords = "CIA, L-asparaginase, Treatment",
author = "A. Reiff and M. Zastrow and Sun, {B. C.} and S. Takei and H. Mitsuhada and B. Bernstein and Durden, {Donald L}",
year = "2001",
month = "12",
day = "1",
language = "English (US)",
volume = "19",
pages = "639--646",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "6",

}

TY - JOUR

T1 - Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase

AU - Reiff, A.

AU - Zastrow, M.

AU - Sun, B. C.

AU - Takei, S.

AU - Mitsuhada, H.

AU - Bernstein, B.

AU - Durden, Donald L

PY - 2001/12/1

Y1 - 2001/12/1

N2 - Objective. To evaluate the safety and efficacy of L-asparaginase as an immunosuppressive agent in a mouse model of rheumatoid arthritis. Methods. Male DBA/1 mice with collagen-induced arthritis (CIA) were treated at different intervals with various doses of native and pegylated L-asparaginase from E. coli. The mice were observed for 4 weeks during which time arthritis was scored. Outcome parameters included effect on severity and progression of established arthritis as well as prevention of disease. In addition, X-rays from the affected joints were obtained for comparison. Results. Both native L-asparaginase at a dose of 50 IU/injection intraperitoneally three days a week and pegylated asparaginase (PEG-L-asparaginase) at a dose of 25 IU/injection twice a week, significantly reduced the mean arthritic score (MAS) in mice with established arthritis (p < 0.001 for PEG-L-asparaginase). When native L-asparaginase was administered before the onset of arthritis (days 14-post immunization) the number of mice developing arthritis as well as the number of arthritic paws and the severity of arthritis in the treatment group were significantly decreased (p < 0.0001). Significant differences were found in the X-ray evaluation between treated and control mice. None of the animals died due to drug related events or showed signs of asparaginase induced toxicity. Conclusion. Our data provide the first direct evidence that L-asparaginase is a potent antiarthritic agent and may represent an effective second line agent for future treatment studies in juvenile and adult rheumatoid arthritis.

AB - Objective. To evaluate the safety and efficacy of L-asparaginase as an immunosuppressive agent in a mouse model of rheumatoid arthritis. Methods. Male DBA/1 mice with collagen-induced arthritis (CIA) were treated at different intervals with various doses of native and pegylated L-asparaginase from E. coli. The mice were observed for 4 weeks during which time arthritis was scored. Outcome parameters included effect on severity and progression of established arthritis as well as prevention of disease. In addition, X-rays from the affected joints were obtained for comparison. Results. Both native L-asparaginase at a dose of 50 IU/injection intraperitoneally three days a week and pegylated asparaginase (PEG-L-asparaginase) at a dose of 25 IU/injection twice a week, significantly reduced the mean arthritic score (MAS) in mice with established arthritis (p < 0.001 for PEG-L-asparaginase). When native L-asparaginase was administered before the onset of arthritis (days 14-post immunization) the number of mice developing arthritis as well as the number of arthritic paws and the severity of arthritis in the treatment group were significantly decreased (p < 0.0001). Significant differences were found in the X-ray evaluation between treated and control mice. None of the animals died due to drug related events or showed signs of asparaginase induced toxicity. Conclusion. Our data provide the first direct evidence that L-asparaginase is a potent antiarthritic agent and may represent an effective second line agent for future treatment studies in juvenile and adult rheumatoid arthritis.

KW - CIA

KW - L-asparaginase

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0035667985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035667985&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 639

EP - 646

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 6

ER -